Reliant
This article was originally published in The Rose Sheet
Executive Summary
Reliant Technologies, Inc., "the pioneer of fractional resurfacing and market leader of aesthetic laser skin treatments," announced its distinction as nation's 157 fastest growing company out of 500 companies by Inc. magazine, according to August 21 release. Inc. magazine also named Reliant fifth in top 50 businesses in Silicon Valley and eighth among top U.S. health companies. In 2004, Reliant Technologies introduced Fraxel platform of lasers, "the most advanced skin resurfacing systems available for dermatologists and cosmetic surgeons," says release. Sales of Fraxel laser systems contributed to company's $70.5 million revenue in 2007, a 1,450 percent increase since 2004. Eric Stang, CEO and president of Reliant Technologies, says that Fraxel brand has become "the gold standard in laser skin resurfacing preferred by physicians and patients alike." The firm recently announced a partnership with electronics giant Philips to develop laser skin-rejuvenation technology for at-home use (1"The Rose Sheet" August 18, 2008, p. 5)
You may also be interested in...
Reliant Links With Philips To Develop Laser Skin-Care Device For Home Use
Reliant Technologies Inc., developer of Fraxel laser systems, has partnered with electronics giant Philips to develop laser skin-rejuvenation technology for use at home, taking a cue from some of the industry's biggest players that are making moves toward the aesthetic devices market
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.